Search - tctmd.com

Displaying 261 - 280 of 325

Sort: Relevancy | Date

News Conference News TCT 2014

I-LOVE-IT 2: Biodegradable Polymer SES as Effective as Durable Polymer SES in All-Comers

September 17, 2014

News Conference News TCT 2014

EVERBIO II: Angiographic Outcomes Similar for BVS, EES, BES

September 17, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

Presenter: Jun-Hyok Oh

September 16, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

September 15, 2014

News Conference News TCT 2014

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

September 15, 2014

News Conference News TCT 2014

Expert Discusses Potential Role for Platelet Function, Genetic Testing

September 15, 2014

News Conference News TCT 2014

COMBO Stent Achieves Neointimal Regression at 24 Months

September 15, 2014

Presentation TCT 2014

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Frederick Feit

September 14, 2014

News Conference News TCT 2014

ADAPT-DES: Stent Thrombosis Increased During First 30 Days After PCI in High-Risk Patients

September 13, 2014

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Advertisement

I-LOVE-IT 2: Biodegradable Polymer SES as Effective as Durable Polymer SES in All-Comers

EVERBIO II: Angiographic Outcomes Similar for BVS, EES, BES

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Comparable outcomes on single use of clopidogrel vs_ dual antiplatelet therapy after coronary stenting in patients with acute myocardial infarction

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

Expert Discusses Potential Role for Platelet Function, Genetic Testing

COMBO Stent Achieves Neointimal Regression at 24 Months

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

ADAPT-DES: Stent Thrombosis Increased During First 30 Days After PCI in High-Risk Patients

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Studies Find Differing Benefits of Platelet, Genotype Testing

OPTIMIZE: 3-Month DAPT Safe with ZES

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content